Our Vision

A world where people return to health as soon as possible.

Ellume COVID-19 Home Test

Ellume’s self-tests provide accurate results in 15 minutes.

New Facility in U.S.

Ellume establishes flagship U.S. manufacturing facility in Maryland

Our Vision

A world where people return to health as soon as possible.

Ellume COVID-19 Home Test

Ellume’s self-tests provide accurate results in 15 minutes.

New Facility in U.S.

Ellume establishes flagship U.S. manufacturing facility in Maryland

Our Vision

A world where people return to health as soon as possible.

Ellume COVID-19 Home Test

Ellume’s self-tests provide accurate results in 15 minutes.

New Facility in U.S.

Ellume establishes flagship U.S. manufacturing facility in Maryland

For Consumers

For Professionals

About Us

We develop, manufacture, and commercialize the next generation of digitally enabled diagnostic products for healthcare professionals and consumers.

For Professionals

Rapid diagnostic products for healthcare professionals at the point of care.

For Consumers

Self-performed tests that provide accurate rapid results directly onto the user’s smartphone.

For Professionals

Rapid diagnostic products for healthcare professionals at the point of care.

For Consumers

Self-performed tests that provide accurate rapid results directly onto the user’s smartphone.

For Professionals

Rapid diagnostic products for healthcare professionals at the point of care.

For Consumers

Self-performed tests that provide accurate rapid results directly onto the user’s smartphone.

Announcement · July 14, 2022

Free tests for blind and low vision people

Ellume manufacturing facility, Frederick MD

Announcement · March 31, 2022

Ellume officially opens production facility in Frederick, Maryland

Announcement · January 10, 2022

Next generation TB test receives approval from key global review panel

A culture of excellence

We are proud of the recognition we have received for our ongoing contributions to the development of innovative emerging technology for the benefit of humanity.

IEEE Advancing Technology for Humanity award

Popular Science Best of What's New award

Financial Review Boss Most Innovative Companies

Australia's Biotechnology Organisation award

Lord Mayor's Business Awards winner 2021

*The Ellume COVID-19 Home Test has not been FDA cleared or approved; but has been authorized by the FDA under an emergency use authorization. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetics Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. **The ellume·lab COVID Antigen Test has not been FDA cleared or approved, but has been authorized by the FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. ***QIAreach™ Anti-SARS-CoV-2 Antigen Test has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

We use cookies

Ellume Limited values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Others are optional: performance cookies show us how you use our website and features; functional cookies remember your preferences; and advertising cookies help us share relevant content. Cookies Policy.

Our Vision

Ellume COVID-19 Home Test

New Facility in U.S.

Our Vision

Ellume COVID-19 Home Test

New Facility in U.S.

Our Vision

Ellume COVID-19 Home Test

New Facility in U.S.

For Professionals

For Consumers

For Professionals

For Consumers

For Professionals

For Consumers

Latest News

A culture of excellence

Sign up for our newsletter